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2. Abstract 
 
Purpose: Anti-tumor necrosis factor (TNF) drugs have been extensively used in non-infectious 
uveitis (NIU), when corticosteroids or conventional immunosuppressive drugs cannot 
adequately control inflammation or intolerable side effects accrue. However, systemic anti-TNF 
therapies are also associated with a myriad of side effects. Therefore, intravitreal administration 
of anti-TNF biologics has been employed to minimize patient morbidity and systemic adverse 
effects, while maintaining therapeutic effectivity. We undertook a systematic review to determine 
evidence of efficacy and safety of intravitreal administration of anti-TNF drugs in adults with 
NIU.  
Methods: We conducted this systematic review according to the PRISMA guidelines. The 
protocol was registered with PROSPERO (CRD42016041946). We searched CENTRAL, 
MEDLINE and EMBASE, from inception to April 2017, as well as clinical trial registries and grey 
literature. The qualitative analysis included all studies of adult patients with a diagnosis of NIU 
and who received intravitreal anti-TNF drugs with a 4-week minimum follow-up.  
Results: A total of 4840 references were considered for title and abstract screening. Seven full-
texts were screened and five studies were considered for analysis. All studies were open-label, 
single-center, prospective, non-randomized, interventional case-series with a follow-up between 
4 and 26 weeks, employing either adalimumab in two studies and infliximab in three. Three 
studies showed a treatment effect of anti-TNF intravitreal injections, while one study revealed 
short-term improvement and one study revealed no efficacy of anti-TNF intravitreal therapy. 
None of the studies reported ocular adverse effects but only two studies included 
electrophysiological assessment in the safety analysis and no study assessed systemic human 
anti-drug antibodies. 
Conclusion: The available evidence is not sufficiently robust to conclude about the clinical 
effectivity of intravitreal anti-TNF in NIU and so no recommendation can be made. Intravitreal 
injection of anti-TNF antibodies remains a possible treatment option to be explored through 
robust clinical investigation. 
 
 
Key-words: non-infectious uveitis, intravitreal, anti-tumor necrosis factor, biologics.  
  
  
3. Text 
Background 
 
Uveitis comprises a heterogeneous group of intraocular inflammatory diseases. (Cordero-Coma 
& Sobrin 2015, Jabs 2005, Levy-Clarke et al. 2014) Non-infectious uveitis (NIU) are thought to 
result from an immune-mediated response to ocular antigens. Immune responses against ocular 
antigens in uveitis remain unknown, although retinal arrestin (also known as Soluble antigen or 
S-Ag) and interphotoreceptor retinoid binding protein (IRBP) have been proposed.(Mattapallil et 
al. 2011) Similarly, mechanisms of disease are not fully elucidated, in part because of the 
heterogeneity of uveitic conditions that we categorise under the umbrella term “NIU”. There is 
evidence that highlights the possibility that both autoinflammatory and autoimmune responses 
are operative in NIU. In particular, where activation of innate immune response leads to 
development of adaptive immune responses.(Janssen et al. 2012, Lee et al. 2014) 
Notwithstanding which pathways are at play, late complications of uveitis, such as cataract, 
glaucoma, or chronic macular edema can be sight threatening,(Androudi et al. 2010, Caspi 
2010, Cordero-Coma & Sobrin 2015, Srivastava, Rajappa & Kaur 2010) and in developed 
countries, they represent one of the leading causes of blindness in the working age population. 
(Durrani et al. 2004) Substantial healthcare costs, workforce absence, leave of absence and 
long-term disability have been associated to NIU.(Thorne et al. 2016). 
Overall, the goals of NIU therapy are to reduce ocular inflammation, avoid damage to 
anatomical structures, and prevent visual loss.(Cordero-Coma & Sobrin 2015, Levy-Clarke et al. 
2014) Although corticosteroids have been the mainstay of therapy, they are often insufficient for 
adequate disease control, and are associated with numerous well-known systemic and local 
complications.(Lin, Suhler & Rosenbaum 2014, Pavesio et al. 2010, Sánchez-Cano et al. 2013) 
When inflammation is not well controlled by corticosteroids or side effects are unacceptable or 
intolerable, systemic immunomodulatory therapy (IMT) should be considered. Current IMT 
options comprise the biologics, such as monoclonal antibodies (mAb) and fusion 
proteins.(Giuliari, Sadaka & Hinkle 2014, Pasadhika & Rosenbaum 2014, Pavesio et al. 2010, 
Srivastava, Rajappa & Kaur 2010)  
Different cytokines and chemokine have been involved in the pathogenesis of uveitis and have 
been shown to be elevated in patients with uveitis.(Carreño et al. 2016) Tumor necrosis factor 
(TNF) has been the leading target for NIU biologic treatment.(Caspi 2010, Cordero-Coma & 
Sobrin 2015, Dick et al. 2004, Nakamura et al. 1994, Srivastava, Rajappa & Kaur 2010) As a 
pleiotropic and multifunctional cytokine, TNF plays a pivotal role in ocular inflammation, via 
  
reactive oxygen species, promotion of angiogenesis and breakdown of the blood-retinal barrier 
(BRB), being associated with the development of sight-threatening NIU-associated 
complications.(Caspi 2006, Caspi 2010, Cordero-Coma & Sobrin 2015, Levy-Clarke et al. 2014, 
Markomichelakis et al. 2012, Pulido et al. 2010, Shim 2011) Anti-TNF drugs have established 
efficacy in several systemic inflammatory conditions related to NIU such as Behçet 
disease(Hatemi et al. 2008), spondyloarthritis(Zochling et al. 2006), sarcoidosis(Maneiro et al. 
2012) or juvenile idiopathic arthritis(Kalinina Ayuso et al. 2014, Ostring & Singh-Grewal 2013).  
The inactivation of TNF can been achieved with mAb, such as infliximab, adalimumab, 
golimumab, and certolizumab-pegol, or with receptor fusion proteins, as etanercept.(Cordero-
Coma & Sobrin 2015, Levy-Clarke et al. 2014, Pulido et al. 2010) Currently these drugs are only 
approved for systemic administration and their route of administration and half-life are 
summarized on Error! Reference source not found. (adapted from Pascual-Camps, 
2014).(Pascual-Camps et al. 2014)   
Although these compounds are approved for other chronic immune-mediated inflammatory 
diseases and have shown positive results in the treatment of NIU (with variable levels of 
evidence and excluding etanercept), their use in NIU remains largely off-label, with the 
exception of adalimumab that was recently licenced after the publication of the VISUAL I and II 
trials.(Schwartzman 2016), (Jaffe et al. 2016, Levy-Clarke et al. 2014, Nguyen et al. 2016, 
Sánchez-Cano et al. 2013, Srivastava, Rajappa & Kaur 2010)  
Several anti-TNF-related adverse effects have been described, such as reactivation of latent 
tuberculosis or hepatitis B virus, invasive fungal infections, central and peripheral neuropathies, 
and induction of immune disturbances.(Cordero-Coma & Sobrin 2015, Lawson, Thomas & 
Akobeng 2006, Levy-Clarke et al. 2014, Ma & Xu 2013, Pulido et al. 2010) Side effects related 
to systemic administration have led to the investigation of intravitreal route of administration, as 
an option that could curtail some of these unwanted effects while preserving therapeutic 
efficacy.(Levy-Clarke et al. 2014, Pascual-Camps et al. 2014) This route of drug delivery has 
been well established in uveitis treated with corticosteroids(Kane et al. 2008, Kempen et al. 
2015, Reddy et al. 2016, Taylor et al. 2012), anti-vascular endothelial growth factor 
(VEGF),(Androudi et al. 2010, Tempest-Roe et al. 2013) or sirolimus.(Ibrahim et al. 2015, Vigil 
et al. 2015) In experimental autoimmune uveitis, intravitreal anti-TNF administration suppresses 
ocular inflammation particularly inhibiting macrophage activation that suppresses structural 
damage and prevents functional loss. Despite no direct effect in systemic cell migration to the 
eye, intravitreal anti-TNF has the opportunity and experimental evidence to curtail cell activation 
at the target site.(Khera et al. 2012) Nonetheless, in man, intravitreal administration of anti-TNF 
  
is poorly studied, and contradictory results with respect to its efficacy and safety in NIU in both 
humans and animal models exist.(Androudi et al. 2010, Arevalo, Serrano & Wu 2013, Farvardin 
et al. 2010, Khalili et al. 2016, Markomichelakis et al. 2012, Pascual-Camps et al. 2014, 
Tempest-Roe et al. 2013) 
The aim of this systematic review is to assess the efficacy and safety of intravitreal 
administration of anti-TNF drugs in adults with NIU, to discern opportunities and unmet needs.  
  
  
  
Methods 
Protocol and registration: 
We conducted this systematic review and meta-analysis according to the PRISMA 
guidelines.(Liberati et al. 2009) The protocol was prospectively registered with PROSPERO 
(registration number: CRD42016041946) and done according to PRISMA-P guidelines.(Moher 
et al. 2015)  
Eligibility criteria: 
All studies, including case reports, case-series, cohorts, case-controls and clinical trials of adult 
patients – aged above 18 years old – with a clinical diagnosis of persistent NIU and where 
patients received intravitreal anti-TNF drugs with a minimum follow-up of 4 weeks. Persistent 
NIU is defined as inflammation of any part of the uvea (choroid, ciliary body and/or iris) that lasts 
for 3 or more months, after an infectious etiology has been excluded, or if there is a high 
suspicion of an immune-mediated underlying mechanism, which may occur isolated or in 
association with a systemic condition.(Jabs 2005) There were no restrictions regarding the 
number of participants reported in studies, year of and language of publication, publication 
status, or etiology of NIU. 
Information sources: 
For the identification of studies considered for inclusion in this review, detailed search strategies 
were developed for each database explored: Medline (from inception to April 2017), EMBASE 
(from inception to April 2017) and CENTRAL (from inception to April 2017). Grey literature was 
retrieved from appropriate databases from inception to April 2017 (www.opensigle.inist.fr; 
www.ntis.gov). Clinical trials registries (www.clinicaltrial.gov; www.clinicaltrialsregistry.eu) were 
also pursued from inception to April 2017. Non-English papers were equally assessed, 
translated as necessary and evaluated for inclusion. Reference lists were crosschecked, and 
whenever necessary, authors of published trials were contacted for further information and 
unpublished data.  
Search:  
The search strategy combined (uveitis) AND (etanercept OR infliximab OR adalimumab OR 
golimumab OR certolizumab). The search was restricted to humans. All terms were searched as 
free-text and as controlled vocabulary.  The search strategies can be found in the Appendix 1. 
Study selection: 
Two independent review authors (DS, IL) assessed the references identified by the search 
strategy, read each of the titles and abstracts of the reports and selected for inclusion the 
appropriate ones. If there was no abstract, the report was retrieved in full text. Then, two review 
  
authors (DS, IL) independently assessed the full-text articles for methodological quality and data 
extraction. Disagreements were resolved by discussion or by consensus with the participation of 
a third author (FBR). 
Data collection process: 
Two review authors (DS, IL) independently extracted the data onto standardized forms and 
crosschecked them for accuracy. Disagreements were resolved by discussion or reached by 
consensus with the participation of a third author (FBR). 
Data synthesis 
Due to the clinical and methodological heterogeneity of the available data, the studies retrieved 
were only qualitatively evaluated. 
  
  
Results 
Before de-duplication, a total of 5675 references were considered (MEDLINE 1582, Embase 
4093, CENTRAL 93). Our grey literature strategy did not retrieve any reference. One reference 
was retrieved by hand-search.(Hamza et al. 2016) De-duplication generated 4840 references 
for screening. After title and abstract screening, seven studies were examined in full-text. Two 
studies were further excluded, one due to inappropriate study design (narrative review (Yeh et 
al. 2012)) and another due to wrong patient population (age-related macular degeneration 
(Giganti et al. 2010)). Five studies enrolling a total of 57 patients were thus included in the final 
analysis: one published in 2010 (Androudi et al. 2010), two published in 2012 (Farvardin, Afarid 
& Shahrzad 2012, Markomichelakis et al. 2012), one published in 2014 (Hamam et al. 2014) 
and one study published in 2016 (Hamza et al. 2016). We did not retrieve any unpublished 
studies. See Figure 1 for the Systematic review flow diagram. 
 
Study characteristics 
All studies were open-label, single-center, prospective, nonrandomized, interventional case-
series. The number of participants in each study ranged from 7 to 20. Overall, the studies 
enrolled a total of 66 eyes from 57 patients, based on an intention-to-treat population. All studies 
evaluated intravitreal injection of anti-TNF in an open-label fashion. Table 1 summarizes 
individuals’ studies characteristics regarding anti-TNF administered drug, dose, number and 
scheme of injections, and duration across studies. The main inclusion criteria were patients with 
active NIU in all but one study – Androudi, 2010, which included patients with controlled uveitis 
and persistent cystoid macular edema (CME) despite control of the inflammation. It is 
noteworthy that all studies bar two included patients with several etiologies of NIU. 
Markomichelakis, 2012 and Hamza, 2016 exclusively included patients with ocular inflammation 
associated with Behçet disease. Table 2 describes demographic characteristics of the enrolled 
subjects, uveitis etiologies, mean disease duration, possibility of concomitant conventional 
immunosuppressive treatment and number of patients naïve to anti-TNF drugs across studies. 
Across all studies, age ranged from 11 to 53 years-old and 32% (n=18) were female. All studies, 
except Farvardin, 2012, included adult patients only. Information about the lens status in each 
patient was provided only in Androudi, 2010.  No study received industry funding. 
 
The main outcome measures were: i) change in central macular thickness (CMT) on optical 
coherence tomography (OCT) in Androudi, 2010; ii) change in best-corrected visual acuity 
(BCVA) and change in CMT on OCT in Hamza, 2016; iii) change in the grade of inflammatory 
  
anterior chamber cells and vitreous haze, change in fluorescein angiography (FA) score, 
change in CMT on OCT and change in electrophysiological tests in Hamam, 2014; iv) change in 
BCVA, change in the grade of inflammatory anterior chamber cells, vitreous haze and posterior 
segment in Markomichelakis, 2012; and v) change in BCVA, change in CMT on OCT, change in 
vitreous haze, number of patients with retinitis, vasculitis and papilitis and change in in 
electrophysiological tests in Hamza, 2016. 
 
Tables 3 and 4 report results in each study regarding efficacy outcomes, namely number of 
patients with CME, mean OCT, mean CMT, mean BCVA, mean anterior chamber cells and 
mean vitreous haze at baseline and day 30 and the general authors’ conclusion about the 
efficacy of the intervention.  
 
CMT measured by OCT significantly decreased in Markomichelakis, 2012 and Farvardin, 2012 
whereas this decrease was not significant in Androudi, 2010. In Hamam, 2014, only the change 
in median CMT between baseline and final visit (week 26) was reported, being statistically 
significant. About the OCT device used to assess the macula, 2 studies used a spectral-domain 
OCT device (Androudi, 2010 and Hamam, 2014), while the other three, used a time-domain 
OCT device. Regarding BCVA change, in Hamza, 2016, Markomichelakis, 2012 and Farvardin, 
2012 there was a significant improvement, whereas in Androudi, 2010 it did not change 
significantly. In Hamam, 2014, it is impossible to draw a similar conclusion since BCVA was only 
reported at baseline and 26 weeks, (at 4 weeks was only the median and interquantile range 
are reported). Anterior chamber cells assessment according to the Standardization of Uveitis 
Nomenclature (SUN)(Jabs 2005)  Working Group reporting is available in Markomichelakis, 
2012 and Hamam, 2014 studies. In the former, a significant decrease in this parameter between 
baseline and week 4 is reported, whereas in Hamam, 2014, information about this parameter is 
only available at baseline and week 26th. The vitreous haze is reported in four studies. In 
Markomichelakis, 2012, Hamam, 2014 and Hamza, 2016 this grading was performed according 
to the SUN(Jabs 2005) , whereas in Farvardin, 2012 this grading was performed according to 
the BIO Score(Neri et al. 2013). In Markomichelakis, 2012, Hamza, 2016 and Farvardin, 2012, a 
significant vitreous haze difference was reported between baseline and week 4. In Hamam, 
2014 study, the progression of the median of the vitreous haze was reported to decrease 
significantly after 26 weeks. 
 
  
Regarding concurrent IMT, in Androudi, 2010 study, 4 patients were on oral IMT (with no further 
specification), one patient was not under nor had history of systemic IMT and 3 patients had a 
previous history of IMT (with no further specification); in Farvardin, 2012 study there is only 
mention to known absence of response to conventional IMT in the previous 3 months in all 
patients; in Hamam, 2014 study prior systemic IMT and results are detailed (patient 1 has 
received prior azathioprine and IFN-α-2a and had inflammation relapse, patient 2 has received 
prior cyclosporine A and discontinued 8 weeks after initiating intravitreal adalimumab, patient 3 
had not received prior IMT and had documented inflammation relapse, patient 4 has received 
prior azathioprine and systemic adalimumab and had treatment failure, patient 5 has received 
prior azathioprine and had treatment failure, patient 6 has received prior methotrexate, IFN-α-2a 
and systemic with infliximab treatment failure and patient 7 received prior methotrexate, 
mycophenolate mofetil and azathioprine and was intolerant to conventional IMT; in  
Markomichelakis, 2012 study, 4 patients did not receive any prior IMT, 5 patients have received 
monotherapy with azathioprine or cyclosporine and 6 patients receiving combination therapy 
with azathioprine and cyclosporine. In this study, a sub-analysis was done to evaluate a 
possible influence of background IMT in these 3 subgroups of patients and statistical analysis 
did not reveal significant differences between the subgroups in all variables studied, including 
BCVA; finally in Hamza, 2016 study all patients received prior azathioprine and/or 
cyclophosphamide and did not suspend their background treatments when entering in the study. 
 
Safety outcomes are detailed in Table 5. Systemic adverse effects were not reported in any 
study. Only in Androudi, 2010, 2 patients discontinued the study due to participants’ preferences 
and one participant was lost to follow-up after the first injection. In the other four studies, there 
were no withdrawals independently of the reason. Only two studies reported 
electrophysiological assessment. No study assessed the development of anti-drug antibodies. 
 
Taking the data together, three small observational studies (Hamam, 2014, Hamza, 2016 and 
Markomichelakis, 2012) showed a treatment effect of anti-TNF intravitreal injections in NIU 
when considering a variety of endpoints that were independently chosen for each study; one 
small observational study (Androudi, 2010) showed no efficacy of anti-TNF intravitreal 
injections, and one (Farvardin, 2012) found a short-term improvement in ocular inflammation 
with anti-TNF intravitreal injections. Finally, although a systematic review was performed 
according to PRISMA(Moher et al. 2015, The Prisma Group from Moher D, Liberati A, Tetzlaff J 
2009) and Cochrane(Higgins & Green 2011) standards, we classified the level of evidence 
  
found  as 3a according to Oxford Center for Evidence-Based Medicine 2011 Levels of 
Evidence(= et al. 2011) and no randomized controlled trials were retrieved in our search.  
  
  
Discussion 
Rationale for intravitreal administration of anti-TNF drugs 
Anti-TNF drugs are widely used in several systemic immune-mediated conditions such as 
spondyloarthritis, rheumatoid arthritis and inflammatory bowel disease.(Markomichelakis et al. 
2012) Specifically, adalimumab is a recombinant human IgG1 monoclonal antibody specific for 
human TNF that blocks this molecule via an interaction with the p55 and p75 cell-surface TNF 
receptors.(Levy-Clarke et al. 2014, Neri et al. 2010, Neri et al. 2011) Infliximab is a monoclonal, 
chimeric (mouse/human) IgG1 κ antibody that binds to the soluble and transmembrane forms of 
TNF.(Cordero-Coma & Sobrin 2015, Suhler et al. 2005)  
Firstly, the recently published VISUAL trials have provided level 1 evidence supporting the 
clinical efficacy of subcutaneous adalimumab in controlling inflammation and reducing the 
frequency of flares with a diverse range of uveitic diagnosis.(Jaffe et al. 2016, Nguyen et al. 
2016) Although not formally approved for NIU, there are an important number of studies with 
infliximab specifically in two underlying conditions: Behçet disease and juvenile idiopathic 
arthritis.(Cordero-Coma & Sobrin 2015, Levy-Clarke et al. 2014) Moreover, evidence of the 
efficacy and safety of adalimumab and infliximab in adult NIU may also be found in case 
reports(Achille et al. 2016, Capote et al. 2014, Ermetcan et al. 2014, Leccese et al. 2011, 
Sakurai et al. 2016, Takase et al. 2011, Zmuda et al. 2013), retrospective case series(Al Rashidi 
et al. 2013, Alfawaz et al. 2014, Dobner et al. 2013, Durrani et al. 2016, Handa et al. 2011, 
Interlandi et al. 2014, Kim et al. 2016, Kruh et al. 2014, Mushtaq et al. 2007, Okada et al. 2012, 
Sobrin et al. 2007, Takeuchi et al. 2014, Vallet et al. 2016, van Denderen et al. 2014) and 
prospective case series.(Diaz-Llopis et al. 2008, Díaz-Llopis et al. 2012, Erckens et al. 2012, 
Joseph et al. 2003, Rudwaleit et al. 2009, Suhler et al. 2013, Suhler EB, Smith JR, Giles TR, 
Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD 2009)  
Secondly, systemic TNF blockade can cause adverse events such as serious infections (notably 
tuberculosis reactivation), heart failure exacerbation and demyelinating disease.(Cordero-Coma 
& Sobrin 2015, Levy-Clarke et al. 2014, Nanau & Neuman 2014) Local treatment of uveitis 
remains useful, namely with steroids in both adult(Holbrook et al. 2015, Kane et al. 2008, 
Kempen et al. 2015, Lowder et al. 2011, Reddy et al. 2016, Tempest-Roe et al. 2013, Zarranz-
Ventura et al. 2014) and pediatric uveitis.(Kempen et al. 2015, Sella et al. 2015, Taylor et al. 
2012, Tomkins-Netzer et al. 2016) Thus, the possibility to administer these drugs directly into 
the eye may minimize systemic adverse effects of anti-TNF drugs, while achieving local 
therapeutic concentrations.(Androudi et al. 2010, Farvardin et al. 2010, Hamam et al. 2014, 
Markomichelakis et al. 2012) In support, intravitreal anti-TNF administration has been studied in 
  
animal models with variable effects regarding efficacy and retinal toxicity.(Giansanti et al. 2008, 
Manzano et al. 2011, Melo et al. 2012, Theodossiadis et al. 2009, Tsilimbaris et al. 2009, Yuksel 
et al. 2014) The aim of the five studies included in our systematic review was to evaluate the 
safety and efficacy of intravitreal injections of anti-TNF drugs.  
 
Although not fully understood, one pivotal purported mechanism in idiopathic NIU is activation 
and expansion of retinal antigen-specific CD4+ T lymphocytes and elaboration of non-specific 
innate immune responses.(Kerr et al. 2008, Khera et al. 2012, Lee et al. 2014) Also, high levels 
of the cytokine TNF in the aqueous humor of patients with NIU have been described in 
literature.(Kuiper et al. 2011, Sijssens et al. 2007) Thus, the inceptive rational for the intravitreal 
use of anti-TNF drugs is based on the efficacy of these drugs in NIU when used 
systemically(Durrani et al. 2016, Interlandi et al. 2014, Lin, Suhler & Rosenbaum 2014, Suhler 
et al. 2005, Vallet et al. 2016) and the capability to rapidly reach therapeutic drug levels in the 
eye when used intravitreally.(Modorati & Miserocchi 2012) One reason that may explain the lack 
of efficacy or long-term efficacy in some of the studies is that their mechanisms of action may 
not be effective when administered locally in the eye, given the systemic nature of the diseases 
underlying the inflammatory process.(Jaffe et al. 2016, Nguyen et al. 2016, Suhler et al. 2005, 
Tempest-Roe et al. 2013) Indeed, even in specific uveitic conditions with inflammation 
classically confined to the eye, such as birdshot chorioretinopathy, a systemic immune deviation 
has been shown.(Daien et al. 2017, Kuiper et al. 2011, Lee et al. 2014, Yang & Foster 2013) In 
the future, the combination of local and systemic anti-TNF therapy may be a reality to achieve 
optimal control of inflammation in NIU, alongside a more favorable safety profile.(Khera et al. 
2012, Lee et al. 2014) 
 
Summary of evidence 
In four of the five included studies, although not long-lasting, a favorable outcome in terms of 
anatomy and function is reported. In Androudi, 2010 intravitreal adalimumab showed no efficacy 
in improving BCVA or decreasing CMT; however, it should be noted that in this particular study, 
all patients had refractory CME at baseline. Uveitic CME is thought to result from increased 
vascular permeability due to the breakdown of BRB and is a major risk factor for vision 
loss(Fardeau et al. 2015, Goldhardt & Rosen 2016) and often difficult to manage.(Androudi et 
al. 2010, Deuter et al. 2016, Fardeau et al. 2015, Goldhardt & Rosen 2016) As long standing 
CME will result in irreversible damage to as a result of outer retinal and photoreceptor damage, 
anatomical resolution of the CME will not lead to improvement in BCVA.(Androudi et al. 2010) 
  
Notwithstanding this fact, in this study, the change in CMT with intravitreal adalimumab from 
baseline to the end of follow-up was not significant, a finding that may in part be explained by 
the small sample size. 
In the five included studies there were no ocular adverse effects reported, although safety 
assessment was limited.  
 
Safety Monitoring 
With intravitreal administration, safety concerns have been raised by the experience of the use 
of anti-TNF in other ocular non-inflammatory conditions.(Yuksel et al. 2014) Specifically, 
infliximab injections may be both retinotoxic (documented with electrophysiology)(Giganti et al. 
2010) and immunogenic.(Giganti et al. 2010, Wu et al. 2011) Only Hamza, 2016 and Hamam, 
2014 included electrophysiological assessment, and their limited data showed that intravitreal 
infliximab and adalimumab, respectively, were not toxic. Another main concern with intravitreal 
anti-TNF is the potential immunogenicity, an adverse effect that has been reported in studies 
with intravitreal anti-TNF for non-uveitic conditions.(Arias et al. 2010, De Freitas et al. 2013, 
Giganti et al. 2010, Semeraro et al. 2013, Theodossiadis et al. 2009, Wu et al. 2011) None of 
the studies reported here demonstrated immunogenicity. However, in uveitic eyes an 
immunogenic reaction or change in pattern of the pre-existent inflammation is difficult to 
assess.(He et al. 2013) No study assessed systemic human anti-drug antibody responses. As 
such we are limited in concluding on the extent of immunogenicity following intravitreal 
administration in inflamed eyes. 
 
Need for repeated injections 
In Hamza, 2016 study, a need for repeated injection was inferred as a result because of 
deterioration in BCVA and increased vitreous haze between week 4 and 6. Markomichelakis, 
2012 study recommends that repeated intravitreal versus intravenous administration of 
infliximab should be trialled.(Markomichelakis et al. 2012) Farvardin, 2012 proposes that the 
beneficial effect of intravitreal infliximab is not long lasting and, therefore, multiple injections may 
be required to achieve optimal inflammation control (Farvardin, Afarid & Shahrzad 2012),  
similarly to the current systemic treatment protocol with adalimumab or infliximab.(Jaffe et al. 
2016, Jaffe et al. 2016, Mushtaq et al. 2007, Suhler EB, Smith JR, Giles TR, Lauer AK, 
Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD 2009) 
 
Limitations and unmet needs 
  
Study designs were disparate across studies, namely regarding the anti-TNF drug used and the 
concentration and number of injections administered.  Baseline population characteristics also 
presented differences, especially with respect to uveitis etiology. In addition, the OCT device 
used to image and measure CMT was different across studies contributing to differences that 
have been acknowledged regarding retinal thickness analysis and segmentation algorithms in 
the several studies.(Mylonas et al. 2009). The fact that concurrent/prior IMT is detailed only in 3 
of 5 studies is a limitation in the interpretation these studies. We therefore emphasize the 
importance of specifically reporting these data, in order to draw more accurate conclusions of 
studies evaluating treatment outcomes in uveitis. 
Finally, all studies had a small sample size. Further well-conducted and properly sized 
randomized controlled trials are needed to ascertain the effects of intravitreal anti-TNF drugs in 
NIU. Future studies should provide more robust and fast evidence of efficacy as well as 
determine intravitreal half-life and toxic effects.(Androudi et al. 2010) Following this step, and 
depending on the nature of the results, comparative, well-designed and adequately powered, 
randomized clinical trials should be sought. (Pulido et al. 2010) 
 
Conclusions 
Overall, the evidence is not sufficiently robust to conclude about the efficacy of intravitreal anti-
TNF in chronic NIU (i.e., any estimate of the effect is very uncertain(Atkins et al. 2004)). The 
analyzed studies could not be directly compared or meta-analyzed due to fundamental 
heterogeneity in study design, inclusion criteria, doses and schema of drug administration, and 
endpoints. The authors conclude that no recommendation can be made and that intravitreal 
injection of anti-TNF antibodies remains a treatment possibility still to be adequately explored.  
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6. Figure and figure legends  
None 
  
  
7. Tables 
Table 1 Summary of the route of administration and half-life of the commercial available monoclonal TNF inhibitors (adapted from Pascual-Camps, 
2014).(Pascual-Camps et al. 2014)   
Generic name Route of administration Half-life (days) 
Adalimumab Subcutaneous injection 14 
Certolizumab 14 
Etanercept 4 to 6 
Golimumab 14 
Infliximab Intravenous infusion 8 to 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2 General features by study 
Study Type of study Number of 
patients/eyes 
Anti-
TNF 
drug 
Dose Number of injections Study 
duration  
Androudi S, 
2010 
Open-label, 
single-center, 
prospective, 
nonrandomized, 
interventional 
case series 
8/8 (but 
results data 
only about 5 
patients due 
to 
withdrawals) 
ADA 
0.5 mg/ 0.05 
mL and 
reinjection 
with an 
escalating 
dose of 1 
mg/0.05 ml 
Three: baseline, 1 month and 2 months and 
reinjection, with an escalating dose of 1 mg/0.05 
ml performed if at least 1 of the following 
retreatment criteria were met during the follow-
up examination: 1) decrease in BCVA by >= 5 
letters compared with previous visit; 2) increase 
in foveal retinal thickness by >=100 microns 
compared with previous visit OCT values 
6 months 
Farvardin M, 
2012 
7/10 IFX 
1.5 mg/0.15 
mL 
Single injection 6 months 
Haman RN, 2014 7/13 ADA 
1.5 mg/0.03 
mL with 
possible 
higher dose 
of 
subsequent 
injections 
(2.5 mg/0.05 
mL) 
Injection at baseline, 2 weeks and then monthly 
for a total of 7 injections. Patients with 
deterioration of BCVA of two or more lines or 
worsening of inflammation by at least 2+ 
cell/haze at any time during follow-up were 
withdrawn; Patients with no or minimal 
improvement (<2+ cells/haze, fluorescein 
leakage and vascular staining) and stable ERG 
received a higher dose of subsequent injections 
(2.5 mg/0.05 mL) 
26 weeks 
Markomichelakis 
N, 2012 
15/15 IFX 
1 mg/ 0.05 
mL 
Single injection 
4 weeks 
Hamza MME, 
2016 
20/20 IFX 
1 mg/0.05 
mL 
Three consecutive intravitreal injections 6 weeks 
apart 
18 weeks 
Legend: TNF: tumor necrosis factor; ADA: adalimumab; IFX: infliximab; BCVA: best corrected-visual acuity; OCT optical coherence tomography; 
ERG: electroretinogram 
 
 
  
  
Table 3 Demographic characteristics of subjects enrolled in all studies 
Study Female 
gender n(%) 
Age in years 
mean ± SD 
(range) 
Inclusion criteria Mean disease 
duration 
Concomitant 
conventional 
immunosuppression  
Naïve to anti-
TNF drugs 
Androudi S, 2010 4 (50.0) 37 ± 0 (23-52) 
Patients with CME, 
despite control of their 
ocular inflammation, who 
had failed previous CME 
therapies 
NS Yes, not all patients NS 
Farvardin M, 2012 6 (85.7) 
26.6 ±12.8 
(11-50) 
Behçet (4), JIA (1), 
multifocal choroiditis and 
panuveitis (1), pars 
planitis (1) with no 
response to conventional 
treatments in the previous 
3 months 
NS NS NS  
Haman RN, 2014 2 (28.6) 37.5 (19-48) 
Behçet uveitis (4 patients) 
and idiopathic (3 patients) 
48 (4-96) 
months 
Yes, not all patients 
5 patients (2 
had had ADA or 
IFX) 
Markomichelakis 
N, 2012 
5 (33.3) 
35.3 ± 8.9 (23-
53) 
Relapsing ocular 
inflammation associated 
with Behçet disease with 
unilateral sight-
threatening posterior 
segment flare  
5.6 ± 4.3 years Yes 13 
Hamza MME, 2016 1 (5.0) 
31.4 ± 3.5 (26-
38) 
Refractory posterior 
uveitis in Behçet's 
disease 
NS Yes 
20 (only 
previous 
conventional 
immunosuppres
sion was 
allowed) 
Legend: CI: confidence interval; CME: cystoids macular edema; JIA: juvenile idiopathic arthritis; NS: not stated; TNF: tumor necrosis factor; TNFi: 
tumor necrosis factor inhibitor; ADA: adalimumab; IFX: infliximab 
 
 
 
 
 
  
 
Table 4 Efficacy outcomes across studies I 
Study Cystoid 
macular 
edema 
at 
baseline 
(number 
of 
patients) 
Cystoid 
macular 
edema 
at day 
30 
(number 
of 
patients) 
Significanc
e of 
change (p-
value) 
OCT CMT 
at 
baseline 
(μm) 
 mean ± 
SD 
(range) 
OCT 
CMT at 
day 30 
(μm) 
mean ± 
SD 
(range) 
Significance 
of change (p-
value) 
BCVA 
baseline 
(logMar) 
mean ± 
SD 
(range) 
BCVA 
day 30 
(logMar) 
mean ± 
SD 
(range) 
Significance of 
change (p-value) 
Androudi S, 
2010 
8 in 8 8 in 8 
Non-
significant 
692 611 Non-significant 1.1* 1.0* Non-significant 
Farvardin M, 
2012 
NS - 
673.2 ± 
338.39 
456.4 ± 
317.46 
0.01 
1.37 ± 
0.14 (1 
to 2.07) 
0.68 ± 
0.56 (0.3 
to 1.78) 
<0.001 
Haman RN, 2014 8 in 13 NS  - 
320 (170 
to 512) 
NS - 0.53* NS - 
Markomichelaki
s N, 2012 
11 in 15 9 in 15 
Non-
significant 
434 (364 
to 504) 
309 (227 
to 391) 
< 0.001 
0.74 
(0.51 to 
0.96) 
0.30 
(0.07to 
0.52) 
< 0.0001 
Hamza MME, 
2016 
NS 
 
- 361 239 < 0.0001 
0.94 ± 
0.32 
0.41± 
0.18 
< 0.0001 
Legend: NS: not-stated; OCT: optical coherence tomography; CMT: central macular thickness; BCVA: best-corrected visual acuity; * after 
conversion to LogMar 
 
 
 
 
 
  
 
  
  
Table 2 Efficacy outcomes across studies II 
Study Mean 
anterior 
chamber 
cells (95% 
CI) 
baseline 
(range) 
Mean 
anterior 
chamber 
cells (95% 
CI) day 30 
(range) 
Significance 
of change (p 
value) 
Mean vitreous 
haze (95% CI) 
baseline 
Mean vitreous haze 
(95% CI) day 30 
Significance 
of change (p 
value) 
Intravitreal 
anti-TNF 
treatment 
considered 
efficacious
? 
Androudi S, 
2010 
NS NS - NS NS - No 
Farvardin M, 
2012 
NS NS - 2.7±0.82 0.95±0.43 < 0.0005 
Yes, but 
temporary 
effect 
Haman RN, 2014 
0.62 
(range: 0-
4) 
NS - 1,19 (0-3) NS - Yes 
Markomichelaki
s N, 2012 
2.13 (1.55-
2.72) 
0.20 (0.0-
0.51) 
< 0.0001 1.73 (1.24-2.22) 0.33 (0.06-0.60) < 0.0001 Yes 
Hamza MME, 
2016 
NS NS - 2 0.2 < 0.0001 
Yes, but 
probable 
temporary 
effect 
Legend: CI: confidence interval; NS: non-significant; TNF: tumor necrosis factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 6 Safety outcomes across studies 
Study Anti-TNF 
antibodies 
determination 
Electrophysiological 
assessment 
Systemic 
adverse effects 
Ocular adverse 
effects 
Withdrawals due to inefficacy/adverse 
effects/other reasons 
Androudi S, 
2010 
No 
 
 
No 0 0 
0/0/2 patients lost due to patients 
preferences, 1 patient lost to follow-up after 
1st injection 
Farvardin M, 
2012 
No 0 0 0/0/0 
Haman RN, 
2014 
Yes 0 0 
1 eye of a patient failed the treatment and 
was removed from the study due to 
worsening of inflammation and VA after the 
4th injection/0/0 
Markomichel
akis N, 2012 
No 0 0 0/0/0 
Hamza MME, 
2016 
Yes 0 
Subconjunctival 
hemorrhage in 4 
patients after 
injection 
0/0/0 
 
Legend: TNF: tumor necrosis factor; VA: visual acuity 
  
  
8. Illustrations and graphics 
None. 
